World TB Day! Overview of Events, News and Messages

Click here to get more info.

Saturday, March 24, is officially World TB Day but there has been a stream of activities, publications, news and messages to let the world not forget about this major infectious disease killer that claims millions of lives each year.


  • On March 7 and 13, the CORE Group sponsored two webinars on pediatric TB which fit well within the focus on childhood TB for this World TB Day. You can access both webinars at
  • March 16, TB Alliance sponsored “U.S. Advocates Workshop on TB Research and Development” at the Gates Foundation Office in Washington, D.C. The objectives of the meeting were to develop messages for TB research and identify opportunities to communicate them, and to align advocacy strategies to enable R&D issues to be incorporated into ongoing TB advocacy. There were representatives from Aeras, American Thoracic Society, AVAC, Global Health Council, Research!America, RESULTS, Treatment Action Group, and others. For more information contact Heather Ignatius,
  • March 19, the Critical Path to TB Drug Regiments (CPTR) sponsored the event “Cure All: A briefing on the most promising TB drug research.” Click here to read a summary of the event on the blog. Video, photos, and slide presentations of the event can be found at
  • March 21, The TB Elimination Caucus in the House of Representative launched with over 80 people in attendance including 35 congressional staffers. The caucus is sponsored by Congressman Elliott Engel (NY), Congressman Don Young (Alaska), and Congressman Gene Greene (Texas). The three Congressmen spoke of strong interest in continued U.S. funding for TB and ideas of gaining greater support for TB in the U.S. Congress. Click here for additional coverage.

Go to to find out about other upcoming events in TB.


Special Announcements

World TB Day Messages

Additional Coverage

More News
17 Sep 2019
Earlier this month, the NIH announced two new Funding Opportunity Annoucnements (FOAs) on the topic of Myeloid-Derived Suppressor Cells (MDSC) as potential therapeutic targets in TB/HIV co-infected patients. The purpose of these FOAs is to invite applications for support of innovative clinical,...
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...